---
layout: default
title: Tretinoin
parent: 僅模型預測 (L5)
nav_order: 1009
evidence_level: L5
indication_count: 10
---

# Tretinoin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Tretinoin: Original Indication Unavailable → Predicted New Indication: Rheumatoid Nodulosis

## One-Sentence Summary

The evidence pack does not contain a confirmed original indication for Tretinoin (DB00755) — it is not currently registered in Singapore and no `original_indications` data was supplied. The TxGNN model's top-ranked prediction is **Rheumatoid Nodulosis** (score 99.84%), but this candidate is currently supported **only by the model's algorithmic score**, with **zero clinical trials and zero literature** identified.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no original indication data provided, and drug has no Singapore registration |
| Predicted New Indication | Rheumatoid Nodulosis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for Tretinoin is not available in this evidence pack, and no original indication is on record to compare against.

For the top-ranked candidate, Rheumatoid Nodulosis, the model rationale itself states that this link is supported *only* by the TxGNN algorithmic score (0.998) — there is no clinical trial or published literature validating any mechanistic connection between Tretinoin and this condition. The prediction should therefore be treated as a hypothesis-generating signal only, not as evidence of biological plausibility.

It is worth noting that other, lower-ranked candidates in this evidence pack (e.g., osteoarthritis, rank 7) do have supporting mechanistic literature — but that literature includes at least one study suggesting retinoic acid may *induce* rather than treat osteoarthritis-like cartilage degradation, illustrating that a high TxGNN score alone does not guarantee a favorable or even directionally correct signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: obtaining this package insert is a blocking data gap — see Next Steps.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction for Rheumatoid Nodulosis is supported by an algorithmic score alone (Evidence Level L5), with no clinical trials, no literature, and no available safety data (warnings/contraindications are a blocking data gap). There is insufficient evidence to advance this candidate.

**To proceed, the following is needed:**
- TFDA/HSA package insert — warnings and contraindications (Blocking gap, DG001): download and parse label PDF
- Drug mechanism of action (MOA) via DrugBank API (High priority gap, DG002)
- Any clinical trial or literature specifically evaluating Tretinoin in rheumatoid nodulosis or related autoimmune joint conditions
- Confirmation of original approved indication(s) for Tretinoin, and Singapore market registration status
- If pursuing lower-ranked candidates with more evidence (e.g., osteoarthritis), a dedicated safety review is needed given conflicting preclinical signals (protective vs. disease-inducing effects of retinoic acid on cartilage)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

